Notice of Particulars of Conformity Assessment Certificates Revoked - NuSep Ltd, Applied Physiology Pty Ltd, Maquet Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and use of therapeutic goods within Australia. The Act was introduced to address the need for a cohesive legal framework governing the therapeutic goods sector, including medicines, medical devices, and blood products. This Act was enacted by the Parliament of Australia, aiming to ensure that therapeutic goods available to consumers are of an acceptable quality, meet safety standards, and provide effective health outcomes. The overarching policy objective of the Act is to protect public health by ensuring that therapeutic goods are safe, of high quality, and perform as claimed. Through mechanisms such as conformity assessment and post-market surveillance, the Act seeks to maintain and enhance the integrity of the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the supply of therapeutic goods in Australia, which includes medicines, medical devices, blood and blood components, tissues, or microorganisms for therapeutic use. This Act has jurisdiction over the entire Commonwealth of Australia and aims to regulate therapeutic goods to ensure they are safe, of acceptable quality, and their benefits outweigh any risks. The Act applies to the manufacture, import, supply, and evaluation of therapeutic goods, and it encompasses a wide range of entities including manufacturers, importers, sponsors, and suppliers. The Act also extends to clinical trials and research involving therapeutic goods. There are various exclusions and exemptions within the Act, such as for therapeutic goods used for personal, non-commercial use, or for goods intended for export and not for supply in Australia. The Act’s application can be further extended or restricted through subordinate instruments, such as regulations and guidelines issued by the Therapeutic Goods Administration. These instruments provide detailed specifications and requirements for the compliance and regulation of therapeutic goods within the scope of the Act.

Key Provisions

The Therapeutic Goods Act 1989 provides various mechanisms to regulate the quality, safety, and efficacy of therapeutic goods in Australia. Section 41ES of the Act allows the Secretary to revoke a conformity assessment certificate under certain circumstances. When the Secretary revokes such a certificate, Section 41EV requires that a notice of particulars of the revocation be published (s 41EV(1)). This notice must include the reason for the revocation, the identity of the certificate holder, and the certificate number (s 41EV(2)). In the case of the notice published by Cheryl McRae, Acting Head of the Office of Devices Authorisation, the revocations of three conformity assessment certificates were detailed. These revocations were made at the request of the respective certificate holders. Entities that hold conformity assessment certificates under the Act are subject to specific obligations. These include maintaining the highest standards of quality and safety for their therapeutic goods and ensuring that any changes to their operations or products are promptly reported to the Therapeutic Goods Administration (TGA). Non-compliance with these obligations can lead to the revocation of their certificates, as seen in the notices published by Cheryl McRae. Certificate holders must also adhere to the conditions set out in their certificates and any additional requirements imposed by the TGA. Breaching the provisions of the Therapeutic Goods Act 1989 can result in significant consequences. For instance, knowingly supplying therapeutic goods that do not meet the standards set by the Act is an offence, punishable by a fine of up to $66,000 for individuals or $330,000 for bodies corporate, as specified in Section 32DA of the Act. Additionally, under Section 33DA, any person who contravenes the Act in a way that causes death or serious injury may face imprisonment for up to ten years. These penalties underscore the importance of compliance with the Act’s requirements to ensure the safety and efficacy of therapeutic goods in the Australian market.